Vor Biopharma (VOR) Registration Filing summary

Company overview and business model

• Clinical-stage company focused on cell and genome engineering to develop therapies for acute myeloid leukemia (AML), targeting approximately 20,000 new U.S. patients annually.

• Develops shielded hematopoietic stem cell (HSC) transplants to protect healthy cells and enable targeted cancer therapies.

• Pairs shielded transplants with targeted therapeutics, including antibody drug conjugates and VCAR33 CAR-T cell therapy, aiming to establish a new standard of care in AML.

Financial performance and metrics

• As of December 31, 2024, 124,776,152 shares of common stock were outstanding; no preferred stock was outstanding.

• Last reported sales price of common stock on March 18, 2025, was $0.8265 per share on Nasdaq Global Select Market.

• The company’s financial statements include a going concern explanatory paragraph from its auditor.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used for working capital, capital expenditures, and general corporate purposes.

• May allocate a portion to invest in or acquire complementary businesses or technologies, though no current plans exist.

• Pending use, proceeds will be invested in investment-grade, interest-bearing securities.